Druva Appoints Scott Morris as Vice President of APJ Sales Organization businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
46 enterprise tech startups to bet your career on in 2021 This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Enterprise tech startups are generally stable during economic downturns.
That makes them good places to work in any climate.
We rounded up the rising enterprise startups where we think you d be smart to take a job this year.
If there s one industry you can bet on during an economic downturn, it s enterprise tech.
According to a report from OpenView Venture Partners, enterprise software is virtually recession-proof. That s because companies, whether they re in tech, finance, retail, or virtually any industry, rely on enterprise software to make their businesses run.
The right scale of fuel : Stamford-based Sema4 eyes more growth by going public
FacebookTwitterEmail
State Rep. Matt Blumenthal, at left, and Sen. Chris Murphy, at center, tour Sema4 s laboratory at 62 Southfield Ave., in Stamford, Conn., on Sept. 18, 2020.Matthew Brown / Hearst Connecticut Media
STAMFORD Health care information provider Sema4 announced Wednesday that it would become a publicly traded company, an ambitious plan intended to catalyze further growth for one of the fastest-expanding firms in Connecticut.
In a move that values the company at approximately $2 billion, Stamford-headquartered Sema4 is going public through a process that offers an alternative to an initial public offering. It would result in Sema4’s shares trading on the Nasdaq Global Market upon the transaction’s expected completion in the second quarter of this year.
Boston biotech Ensoma lands $70m in funding, partnership with Takeda
By Anissa Gardizy Globe Staff,Updated February 11, 2021, 7:00 a.m.
Email to a Friend
Thereâs no shortage of local
biotechs working in the field of genomic medicine, but something still keeps investor Kush Parmar up at night: The managing partner at Boston venture capital firm 5AM Ventures knows the emerging treatments
wonât be widely accessible to patients.
Some forms of gene therapy and gene editing require a patientâs cells to be removed and reinserted into the body. Others involve cell donors, or initial steps such as chemotherapy â treatments that can only be done in specialized centers or that require days of hospitalization.
Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding
February 11, 2021 at 9:15 am
Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo)
New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology developed over two decades by Seattle researchers Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center and Dr. André Lieber of the University of Washington School of Medicine.
The company will be based in Boston because the city “is the epicenter of biotech and Ensoma could quickly draw the talent, not only for research but as the company scales in manufacturing and clinical development,” said Paula Soteropoulos, the company’s executive chairman. The company’s lead investor and top leadership are also in Boston.